Goodwin’s IP litigation team achieved a trial victory for Dr. Reddy’s Laboratories in a patent infringement case brought by Indivior Inc. and MonoSol Rx involving the drug Suboxone®, an under-the-tongue film strip indicated for the treatment of opioid addiction. In the trial decision, U.S. District Judge Richard Andrews found that Dr. Reddy’s did not infringe any of the three patents asserted by Indivior. Shares of Dr. Reddy’s climbed nearly 10% on the news.
Dr. Reddy’s Laboratories is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The Goodwin team was led by partners Ira Levy, Elaine Blais, Rob Cerwinski and Rob Frederickson and included associates Coy Stull, Molly Grammel, Alex Lu and Katie Kosinski; and paralegals Al Lessard and Alex Shaw.